Comparing Adoption of Breakthrough and "Me-too" Drugs among Medicare Beneficiaries: A Case Study of Dipeptidyl Peptidase-4 Inhibitors.
Inmaculada HernandezYuting Zhang
Published in: Journal of pharmaceutical innovation (2017)
The breakthrough drug sitagliptin had a much longer adoption life compared to the "me-too" drug saxagliptin, and the breakthrough drug sitagliptin was adopted quicker among managed care plans compared to PDP plans.